Vaso Corp
vasocorporation.comVaso Corp (OTCQX: VASO) is a healthcare technology company that operates across three segments: IT services, professional sales services, and proprietary medical equipment. Revenue comes from managed network services sold through its NetWolves subsidiary, commission-based sales of GE HealthCare (GEHC) imaging and diagnostic equipment through its VasoHealthcare channel partner business, and direct sales of proprietary cardiovascular and ambulatory monitoring devices under the EECP and Biox brands. Total revenues were $89.1 million for the year ended December 31, 2025, up from $86.8 million in FY2024. The IT segment contributed $42.5 million in FY2025. The company reported net income of $1.6 million in FY2025, compared to $951,000 in FY2024, with a goodwill impairment charge of $4.6 million also recorded in FY2025. Vaso Corp is headquartered in Plainview, New York and employed 282 full-time persons as of December 31, 2025. Common stock trades on the OTCQX under the symbol VASO and the company has never paid a cash dividend.
Products & Services
EECP therapy systems for cardiovascular treatment; Biox ambulatory monitoring systems including ARCS analysis and report software; MobiCare wireless patient monitoring; NetWolves managed network services including multi-network design, redundancy, application device management, real-time monitoring, and reporting; GEHC diagnostic imaging equipment sales and service as a channel partner.
Revenue Model
Three revenue streams: (1) managed network services fees through NetWolves, a multi-network managed service provider; (2) commissions and revenues from acting as a GEHC channel partner selling imaging and diagnostic equipment to healthcare customers; (3) direct product sales and service contracts for proprietary EECP cardiovascular therapy systems and Biox ambulatory cardiac monitoring systems, with sales in the U.S., China, and international markets through independent distributors.
Customers & Markets
Healthcare providers and hospitals purchasing GEHC diagnostic imaging equipment; healthcare facilities using EECP cardiovascular therapy systems; clinical and ambulatory monitoring customers using Biox cardiac monitors; enterprise and healthcare customers purchasing managed network services through NetWolves.
Geographic Exposure
Primary operations in the United States. Proprietary medical equipment sold directly in the U.S. and China, and through independent distributors in international markets. China-based manufacturing subsidiaries (LET and Biox) support the equipment segment. Biox products hold CE Mark certification for Europe, CFDA approval for China, U.S. FDA clearances, and Brazilian ANVISA approval as of the FY2025 10-K filing.
Financial Snapshot
Loading...
